Phenylbutyrate Therapy for Maple Syrup Urine Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 2, 2017

Study Completion Date

December 31, 2017

Conditions
Maple Syrup Urine Disease
Interventions
DRUG

Phenylbutyrate

Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.

DRUG

Placebo powder

Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

Brendan Lee

OTHER

NCT01529060 - Phenylbutyrate Therapy for Maple Syrup Urine Disease | Biotech Hunter | Biotech Hunter